Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Immunotherapy in colorectal cancer: rationale, challenges and potential
K Ganesh, ZK Stadler, A Cercek… - Nature reviews …, 2019 - nature.com
Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …
established as a major treatment modality for multiple types of solid cancers, including a …
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
M Thibaudin, JD Fumet, B Chibaudel, J Bennouna… - Nature Medicine, 2023 - nature.com
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …
Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion
D Chakravarty, A Johnson, J Sklar… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …
membership following publication or presentation of potentially practice-changing data from …
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
WK Chatila, JK Kim, H Walch, MR Marco, CT Chen… - Nature medicine, 2022 - nature.com
The incidence of rectal cancer is increasing in patients younger than 50 years. Locally
advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and …
advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and …
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is
approved by the US Food and Drug Administration for the treatment of microsatellite …
approved by the US Food and Drug Administration for the treatment of microsatellite …
The association between tumor mutational burden and prognosis is dependent on treatment context
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
[HTML][HTML] ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …
Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …
thousands of mutations most frequently located in monomorphic microsatellites and are …